BioLineRx Ltd. (NASDAQ:BLRX) Short Interest Down 16.2% in November

BioLineRx Ltd. (NASDAQ:BLRX) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 921,900 shares, a drop of 16.2% from the November 15th total of 1,100,000 shares. Based on an average daily trading volume, of 840,800 shares, the short-interest ratio is presently 1.1 days.

Analyst Ratings Changes

BLRX has been the topic of a number of recent analyst reports. HC Wainwright reduced their price target on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, November 25th. StockNews.com assumed coverage on BioLineRx in a research report on Tuesday, December 10th. They issued a “hold” rating for the company.

BioLineRx Stock Performance

BLRX stock remained flat at $0.22 during trading on Friday. 973,980 shares of the company were exchanged, compared to its average volume of 493,844. The firm’s 50-day moving average is $0.39 and its 200 day moving average is $0.57. The stock has a market cap of $17.98 million, a P/E ratio of -1.02 and a beta of 1.39. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. BioLineRx has a 52-week low of $0.21 and a 52-week high of $1.77.

Hedge Funds Weigh In On BioLineRx

Hedge funds have recently bought and sold shares of the stock. CVI Holdings LLC purchased a new stake in shares of BioLineRx in the second quarter valued at $462,000. Atria Investments Inc boosted its stake in BioLineRx by 27.9% in the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after buying an additional 29,193 shares during the last quarter. Finally, PVG Asset Management Corp purchased a new stake in BioLineRx in the 2nd quarter valued at about $70,000. Hedge funds and other institutional investors own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.